Booking Gains on Keryx and What to Look for Next
Research - Why we're booking gains on Keryx (KERX) and an options strategy for the Sept. 7 PDUFA decision on Zerenex.
Read nowSearch Results for keryx
FDA Kicks the Can Down the Road for Keryx’s Lead Drug
Insights - The FDA extended the approval decision date for Zerenex (ferric citrate) by 3 months, to September 7, following revisions to Keryx’s new drug application.
Read nowData Support Keryx’s Anemia Drug in a New and Large Market
Research - Keryx Biopharmaceuticals (KERX) announced on Tuesday that a phase 2 study of Zerenex (ferric citrate) in non-dialysis dependent chronic kidney disease (CKD) patients with elevated … Continue Reading
Read nowSolid Showing At WCN Conference For Keryx: Catalysts Still To Come
Long Ideas - Keryx Biopharmaceuticals (KERX) presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology (WVN) meeting during a … Continue Reading
Read nowKeryx: Attractive In Front Of Catalyst-Rich Second Half
Long Ideas - Shares of Keryx Biopharmaceuticals (KERX) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to … Continue Reading
Read now
Keryx, Zerenex, and IP Protection: A PropThink Conference Call
Interviews - On April 11, PropThink hosted an Interview and Q&A (via conference call) for PropThink subscribers with Dr. Scott Chambers, a leading patent attorney and former … Continue Reading
Read nowHere Are the Reasons to Own Keryx, and Why Key Catalysts are De-Risked
Long Ideas - Following PropThink’s conference call with Dr. Scott Chambers on Thursday, we’re quite comfortable with the short-term and long-term patent protection on Zerenex, Keryx’s (KERX) novel … Continue Reading
Read now